Tardive dyskinesia (TD)—a common movement disorder affecting people with schizophrenia after long-term antipsychotic use—may be linked to inherited differences in oxidative-stress and dopamine-related genes, according to a new review. The findings suggest that variants in superoxide dismutase (SOD), the dopamine D3 receptor gene DRD3 Ser9Gly (rs6280), and BDNF Val66Met (rs6265) may help explain why some patients develop TD.
What’s next: more specific research priorities
- Prospective cohorts in first-episode schizophrenia: Follow antipsychotic-naive patients for 12–24 months, with standardized TD assessments (e.g., AIMS) every 3 months and detailed antipsychotic type, dose, and cumulative exposure.
- Larger, multicenter samples: Aim for adequately powered replication (e.g., ≥1,000 cases and controls) rather than small candidate-gene studies.
- Specific variant and pathway analyses: Test SOD2 Ala16Val (rs4880), DRD3 Ser9Gly (rs6280), and BDNF Val66Met (rs6265), plus gene–gene and gene–environment interactions.
- Functional assays: Measure erythrocyte SOD activity, mitochondrial SOD2 function, plasma oxidative-stress markers (e.g., MDA, 8-OHdG), and DRD3/BDNF-related signaling to clarify biological mechanisms.
- Diverse populations: Replicate findings in East Asian, African, and European ancestry cohorts to assess generalizability.
- Harmonized meta-analysis: Pool studies using consistent TD definitions, assessment scales, and antipsychotic-exposure measures.
- Pharmacogenomic risk models: Develop and validate combined genetic–clinical risk scores, including sex-stratified analyses, before any clinical monitoring use.
link of study:https://onlinelibrary.wiley.com/doi/pdf/10.1155/2022/5748924
